IRF5 is associated with adverse postoperative prognosis of patients with non-metastatic clear cell renal cell carcinoma
PDF | HTML | How to cite
Metrics: PDF 1472 views | HTML 2062 views | ?
Qi Bai1,*, Li Liu1,*, Yu Xia1,*, Jiajun Wang1, Wei Xi1, Yang Qu1, Ying Xiong1, Qilai Long1, Jiejie Xu2 and Jianming Guo1
1Department of Urology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
2Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China
*These authors contributed equally to this work
Jiejie Xu, email: [email protected]
Jianming Guo, email: [email protected]
Keywords: clear cell renal cell carcinoma, IFN regulatory factor-5, nomogram, overall survival, recurrence free survival
Received: November 24, 2016 Accepted: April 25, 2017 Published: May 11, 2017
Background: IRF5 is one member of IRFs family, and is critical for host immunity and cell response. In the present study, we sought to search the clinical and prognostic value of IFR5 in patients with non-metastatic ccRCC.
Results: IRF5 proved to be an adverse independent prognostic factor for overall survival (p < 0.001) and recurrence free survival (p = 0.002). The newly built nomograms could give better prediction for overall survival and recurrence free survival in ccRCC patients.
Materials and Methods: We included 264 individuals who were diagnosed with non-metastatic clear cell renal cell carcinoma in the present study. Immunohistochemistry staining was performed on tissue microarrays to evaluate the IRF5 expression. χ2 test, Fisher's exact test, t test, Kaplan-Meier method and Cox proportional hazard model were applied to evaluate the prognostic value of IRF5. Two nomograms were constructed to predict clinical outcomes for ccRCC patients after surgery.
Conclusions: IRF5 was an adverse independent prognostic factor for both overall survival and recurrence free survival in patients with non-metastatic ccRCC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.